Brand Name

Lexapro

Generic Name
Escitalopram
View Brand Information
FDA approval date: August 14, 2002
Classification: Serotonin Reuptake Inhibitor
Form: Tablet, Capsule, Solution

What is Lexapro (Escitalopram)?

Escitalopram is indicated for the treatment of: major depressive disorder in adults and pediatric patients 12 years of age and older., generalized anxiety disorder in adults and pediatric patients 7 years of age and older. Escitalopram is a selective serotonin reuptake inhibitor indicated for the:, treatment of major depressive disorder in adults and pediatric patients 12 years of age and older , treatment of generalized anxiety disorder in adults and pediatric patients 7 years and older
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Pupillometry in DSWPD Type 1 and Type 2

Summary: The goal of this observational study is to characterize the pupil light response in patients with delayed sleep-wake phase disorder. A subset of participants will take part in a clinical trial to determine if increasing serotonin can alter the circadian response to light. The main questions it aims to answer is: Are there differences in the light response in patients with delayed sleep-wake phase ...

An Open-Label, Randomized Controlled Trial of Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Summary: A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, respon...

Therapeutic Drug Monitoring-Guided Treatment With Sertraline, or Escitalopram in Hospitalized Adults and Children

Summary: Depression in childhood and adolescence is a serious and increasing public-health problem associated with profound short- and long-term consequences, including impaired social and educational functioning, increased risk of somatic illness and substance use, and elevated mortality from suicide. Up to half of depressive disorders beginning in youth persist into adulthood, and the COVID-19 pandemic, ...